Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL).
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Rosiglitazone (Primary) ; Fenofibrate
- Indications Hypercholesterolaemia; Hypertriglyceridaemia
- Focus Pharmacodynamics
- Acronyms RAFAEL
- 07 Jun 2017 Biomarkers information updated
- 25 Feb 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 07 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.